← 產業報告目錄
Diabetic Macular Edema Market Size, Share & Trends Analysis Report By Drug Type (Anti-VEGF (Ranibizumab (Lucentis), Aflibercept (Eylea)), Corticosteroid Therapies (Dexamethasone (Ozurdex), Fluocinolone Acetonide (Iluvien)), Others), By Form (Intravitreal Injections, Intravitreal Implants), By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-17頁數 167報告編號 INSIGHTACE-95c0198e94
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Diabetic Macular Edema Market stood at USD 3.95 billion in 2023, and is projected to reach USD 4.56 billion by 2031, recording a CAGR of 1.9% from 2024 through 2031.
At its core, Diabetic Macular Edema pertains to an ocular disorder associated with diabetes, characterized by fluid accumulation in the macula, resulting in swelling and impaired central vision. Stakeholders across the healthcare landscape are mountingly turning to these solutions to meet contemporary demands.
The market's upward path is propelled by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region projected to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Diabetic Macular Edema Market Snapshot
Chapter 4. Global Diabetic Macular Edema Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Diabetic Macular Edema Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Diabetic Macular Edema Industry Trends
Chapter 5. Diabetic Macular Edema Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug
5.2.1. Anti-VEGF
5.2.1.1. Ranibizumab (Lucentis)
5.2.1.2. Aflibercept (Eylea)
5.2.2. Corticosteroid Therapies
5.2.2.1. Dexamethasone (Ozurdex)
5.2.2.2. Fluocinolone Acetonide (Iluvien)
5.2.3. Others
Chapter 6. Diabetic Macular Edema Market Segmentation 2: By Form, Estimates & Trend Analysis
6.1. Market Share by Form, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Forms:
6.2.1. Intravitreal Injections
6.2.2. Intravitreal Implants
Chapter 7. Diabetic Macular Edema Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
7.2.1. Hospitals
7.2.2. Specialty Clinics
7.2.3. Mail Order Pharmacies
Chapter 8. Diabetic Macular Edema Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Diabetic Macular Edema Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.2.3. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.2.4. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.3. Europe
8.3.1. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.3.3. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.3.4. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.4.3. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.4.4. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.5. Latin America
8.5.1. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.5.3. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.5.4. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.6.3. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.6.4. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Novartis AG
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Bayer AG
9.2.3. Allergan Plc.
9.2.4. F. Hoffmann-La Roche Ltd.
9.2.5. Alimera Sciences Inc.
9.2.6. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
9.2.7. KalVista Pharmaceuticals
9.2.8. Genentech
9.2.9. Oxurion (fka ThromboGenics)
9.2.10. Ocugen, Inc
9.2.11. Regeneron Pharmaceuticals, Inc.
9.2.12. Clearside Biomedical
9.2.13. Daiichi Sankyo
9.2.14. Arctic Vision
9.2.15. Chugai Pharmaceutical Co., Ltd.
9.2.16. Sanofi
9.2.17. Novartis AG
9.2.18. Sun Pharmaceutical Industries Ltd.
9.2.19. Aurobindo Pharma
9.2.20. Lupin
9.2.21. Allergan
9.2.22. Merck & Co., Inc.
9.2.23. Pfizer Inc.
9.2.24. GlaxoSmithKline plc
9.2.25. IRIDEX Corporation
9.2.26. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們